Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerBiomarker

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798895

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798895

Genetic Cancer Biomarkers

PUBLISHED:
PAGES: 276 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Genetic Cancer Biomarkers Market to Reach US$13.9 Billion by 2030

The global market for Genetic Cancer Biomarkers estimated at US$5.2 Billion in the year 2024, is expected to reach US$13.9 Billion by 2030, growing at a CAGR of 17.6% over the analysis period 2024-2030. OMICS, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Bioinformatics segment is estimated at 20.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 22.9% CAGR

The Genetic Cancer Biomarkers market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 22.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 13.3% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.0% CAGR.

Global Genetic Cancer Biomarkers Market - Key Trends & Drivers Summarized

Why Are Genetic Biomarkers Gaining Importance in Cancer Diagnosis and Treatment?

Genetic cancer biomarkers are DNA or RNA-based indicators that reveal the presence, progression, or treatment responsiveness of tumors. These biomarkers are used for early detection, prognosis evaluation, therapy selection, and recurrence monitoring. As cancer research evolves toward personalized treatment strategies, genetic biomarkers play an essential role in matching therapies to individual tumor profiles. This approach reduces trial-and-error in drug administration and improves treatment outcomes.

Applications range from identifying inherited cancer risk to detecting acquired mutations within tumors. Biomarkers such as BRCA1/2, EGFR, KRAS, and BRAF help guide therapeutic decisions in breast, lung, colorectal, and melanoma cases. Non-invasive sampling techniques, including liquid biopsies, are improving the accessibility of genetic testing, enabling more frequent monitoring. The growing adoption of companion diagnostics by oncology specialists is further establishing the role of genetic biomarkers in clinical practice.

How Are Technological Advances Enhancing Biomarker Detection and Interpretation?

High-throughput sequencing technologies such as next-generation sequencing (NGS) and digital PCR are enabling faster, more accurate identification of cancer-associated mutations. These tools allow simultaneous analysis of multiple genes with high sensitivity, even from small or degraded samples. Computational platforms now support variant calling, mutation annotation, and predictive analytics, improving biomarker interpretation and clinical decision-making.

Integration of artificial intelligence and machine learning is refining biomarker classification by analyzing genomic patterns across large patient cohorts. Cloud-based platforms enable sharing of anonymized genomic data for research and therapeutic development. Laboratory-developed tests and FDA-approved panels are expanding the range of actionable biomarkers for solid tumors and hematologic malignancies. As molecular diagnostics continue to evolve, bioinformatics and data integration are becoming essential to managing the increasing complexity of cancer genomics.

Where Are Genetic Biomarkers Being Adopted Most Widely in Oncology?

Hospitals, cancer centers, and reference laboratories are the primary users of genetic cancer biomarker testing. In high-income countries, biomarker testing is integrated into standard care pathways for several cancers, including non-small cell lung cancer, colorectal cancer, and breast cancer. Testing is used to assess therapy eligibility, predict resistance, and monitor minimal residual disease. Oncology practices in emerging markets are also adopting biomarker testing through partnerships with diagnostic labs and pharmaceutical companies.

Biopharmaceutical firms rely on biomarkers for patient stratification in clinical trials, especially for immunotherapy and targeted therapies. Precision oncology programs and cancer registries use genetic profiling to track mutation prevalence and treatment outcomes. As access to NGS platforms and genetic counseling improves, community oncology practices are incorporating biomarker testing into routine workflows. Adoption is growing across both academic and commercial segments of cancer care.

What Is Driving Growth in the Genetic Cancer Biomarkers Market?

Growth in the genetic cancer biomarkers market is driven by several factors related to molecular diagnostics integration, therapy personalization, and sequencing accessibility. Increased use of biomarker-guided treatment in oncology care is supporting demand for comprehensive mutation panels and companion diagnostics. Advances in NGS, liquid biopsy, and digital PCR are enabling faster, minimally invasive, and highly sensitive mutation detection. Growth is also supported by the development of targeted drugs that require biomarker identification, expansion of oncology-focused clinical trials, and reimbursement progress for genetic testing. As precision medicine continues to transform cancer care, genetic biomarkers are central to diagnostic innovation and therapeutic alignment.

SCOPE OF STUDY:

The report analyzes the Genetic Cancer Biomarkers market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (OMICS, Bioinformatics, Other Technologies); Cancer Type (Breast Cancer, Prostate Cancer, Leukemia, Other Cancer Types)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Abbott Laboratories
  • Agilent Technologies
  • Amgen Inc.
  • Bio-Rad Laboratories
  • Bio-Techne Corporation
  • BGI Genomics
  • Caris Life Sciences
  • Danaher Corporation (Cepheid, Beckman Coulter)
  • Exact Sciences Corporation
  • Foundation Medicine (Roche)
  • Fulgent Genetics
  • Guardant Health
  • Illumina, Inc.
  • Invitae Corporation
  • Myriad Genetics
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Roche Diagnostics
  • Thermo Fisher Scientific
  • Veracyte, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38877

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Genetic Cancer Biomarkers - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Focus on Personalized and Precision Oncology Drives Adoption of Genetic Biomarkers for Cancer Diagnosis and Treatment Selection
    • Advancements in Next-Generation Sequencing (NGS) and Genomic Profiling Enable High-Throughput Identification of Cancer-Associated Mutations
    • Increased Use of Companion Diagnostics With Targeted Therapies Strengthens Clinical Utility of Genetic Biomarkers
    • Growing Pipeline of Biomarker-Driven Immunotherapies Promotes Demand for Predictive and Prognostic Genetic Testing
    • Integration of Liquid Biopsy Technologies Enhances Early Detection and Monitoring Through Circulating Tumor DNA (ctDNA) Biomarkers
    • Regulatory Approvals and Reimbursement Support for Genomic Testing Boost Market Adoption in Clinical Oncology
    • Rising Incidence of Cancer Globally Expands Screening Programs and Biomarker-Based Risk Stratification Approaches
    • Partnerships Between Biotech Companies and Diagnostic Labs Accelerate Development of Multi-Gene Panels for Tumor Profiling
    • Expansion of Cancer Genomic Databases and AI-Powered Bioinformatics Platforms Enhances Biomarker Discovery and Interpretation
    • Growing Application of Pharmacogenomics in Cancer Treatment Planning Supports Demand for Germline and Somatic Mutation Analysis
    • Increased Role of Biomarkers in Monitoring Minimal Residual Disease (MRD) Strengthens Use Cases Beyond Initial Diagnosis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Genetic Cancer Biomarkers Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Genetic Cancer Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for OMICS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for OMICS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for OMICS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bioinformatics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Bioinformatics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • JAPAN
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • CHINA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • EUROPE
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Genetic Cancer Biomarkers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • FRANCE
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • GERMANY
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • INDIA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Genetic Cancer Biomarkers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Genetic Cancer Biomarkers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030
  • AFRICA
    • Genetic Cancer Biomarkers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Genetic Cancer Biomarkers by Technology - OMICS, Bioinformatics and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Genetic Cancer Biomarkers by Technology - Percentage Breakdown of Value Sales for OMICS, Bioinformatics and Other Technologies for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Genetic Cancer Biomarkers by Cancer Type - Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Genetic Cancer Biomarkers by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Prostate Cancer, Leukemia and Other Cancer Types for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!